BAP1-inactivated melanocytic tumors represent a subset of epithelioid melanocytic neoplasms resulting from biallelic inactivation of the BAP1 gene and by a driver mutation that activate the MAP kinase pathway, most commonly BRAFV600E. They occur sporadically or, less common, in the setting of BAP1 tumor predisposition syndrome caused by a BAP1 germline mutation that predisposes to several malignancies including cutaneous and uveal melanoma. To date, only few cases of BAP1-inactivated melanomas have been reported. We present a case of a 35-year-old woman presented with a melanocytic lesion microscopically composed of 3 distinct melanocytic populations, suggesting a stepwise progression model to melanoma from a conventional nevus through a melanocytoma stage. This progression was also supported from a molecular viewpoint given BRAFV600E, BAP1, and TERT-p hot spot mutations detected by targeted mutational analysis. Four atypical melanocytic lesions were removed from the patient's back, and the same A BAP1 c.856A>T, p.(Lys286Ter) mutation was detected on either tumoral or normal tissue samples. To the best of our knowledge, this is the first case of BAP1-inactivated melanoma with a documented TERT-p hot spot mutation manifesting as the first presentation of BAP1 tumor predisposition syndrome.

Bioptical Laboratory Pilsen Czech Republic

Department of Dermatology Universisty Hospital Zurich Switzerland

Department of Pathology University Hospital Campus Bio Medico Rome Italy

IDP Institut für Dermatohistopathologie Pathologie Institut Enge Zürich Switzerland

Sikl's Department of Pathology Medical Faculty in Pilsen Charles University Prague Pilsen Czech Republic; and

Zobrazit více v PubMed

Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43:1018–1021.

Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol. 2012;36:818–830.

Blokx WAM, Rabold K, Bovenschen HJ, et al. NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report. Virchows Arch. 2015;466:117–121.

Donati M, Martinek P, Kastnerova L, et al. RAF1 gene fusions as a possible driver mechanism in rare BAP1-inactivated melanocytic tumors: a report of 2 cases. The Am J Dermatopathology. 2020;42:961–966.

Garfield EM, Walton KE, Quan VL, et al. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors. J Am Acad Dermatol. 2018;79:525–534.

Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856–859.

Njauw CNJ, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7:e35295.

Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92:974–980.

Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022–1025.

Wiesner T, Fried I, Ulz P, et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol. 2012;30:e337–e340.

Busam KJ, Sung J, Wiesner T, et al. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. Am J Surg Pathol. 2013;37:193–199.

Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer. 2013;13:153–159.

Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68:6953–6962.

Fischer AS, High WA. The difficulty in interpreting gene expression profiling in BAP-negative melanocytic tumors. J Cutan Pathol. 2018;45:659–666.

Gammon B, Traczyk TN, Gerami P. Clumped perinuclear BAP1 expression is a frequent finding in sporadic epithelioid Spitz tumors. J Cutan Pathol. 2013;40:538–542.

Donati M, Martinek P, Steiner P, et al. Novel insights into the BAP1-inactivated melanocytic tumor. Mod Pathol. 2021;35:664–675.

Elder DE, Massi D, Scolyer RA, et al. WHO Classification of Skin Tumours. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2018.

Murali R, Wilmott JS, Jakrot V, et al. BAP1 expression in cutaneous melanoma: a pilot study. Pathology. 2013;45:606–609.

Ardakani NM, Palmer DL, Wood BA. BAP1 deficient malignant melanoma arising from the intradermal component of a congenital melanocytic naevus. Pathology. 2015;47:707–710.

Marušić Z, Buljan M, Busam KJ. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome. J Cutan Pathol. 2015;42:406–412.

Gerami P, Yélamos O, Lee CY, et al. Multiple cutaneous melanomas and clinically atypical moles in a patient with a novel germline BAP1 mutation. JAMA Dermatol. 2015;151:1235–1239.

Aung PP, Nagarajan P, Tetzlaff MT, et al. Melanoma with loss of BAP1 expression in patients with No family history of BAP1-associated cancer susceptibility syndrome: a case series. Am J Dermatopathol. 2019;41:167–179.

Grisham EA, Tadros J, Smith E. Unique dermoscopic and histopathologic features of melanoma arising in a patient with BAP1 tumor predisposition syndrome. Cureus. 2021;13:e17485.

Zhou Y, Nelson AC, He Y, et al. Gene expression and mutational profile in BAP-1 inactivated melanocytic lesions of progressive malignancy from a patient with multiple lesions. Genes (Basel). 2021;13:10.

Cohen JN, Yeh I, Mully TW, et al. Genomic and clinicopathologic characteristics of PRKAR1A-inactivated melanomas: toward genetic distinctions of animal-type melanoma/pigment synthesizing melanoma. Am J Surg Pathol. 2020;44:805–816.

Lee S, Barnhill RL, Dummer R, et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci Rep. 2015;5:11200.

Isales MC, Khan AU, Zhang B, et al. Molecular analysis of atypical deep penetrating nevus progressing to melanoma. J Cutan Pathol. 2020;47:1150–1154.